Aeterna Zentaris Inc. (AEZS) Testing Investors’ Patience Right Now


JPMorgan Securities LLC (Investme.. recently announced the acquisition of new stake in Aeterna Zentaris Inc. (NASDAQ:AEZS). The institutional investor has increased its shareholding in the Healthcare company by 0.77% to 91800.0 shares with purchase of 700.0 shares. This fresh investment now brings its stake to 0.22% valued currently at $43146.0. In addition, Morgan Stanley Canada Ltd. raised its holdings by 900.0 to 54000.0 shares. And Virtu Financial BD LLC has lifted its position by 126.85% or 27164.0 shares – to 48579.0 shares.

With over 2.73 million Aeterna Zentaris Inc. (AEZS) shares trading Friday and a closing price of $0.50 on the day, the dollar volume was approximately $1.36 million. The shares have shown a negative weekly performance of -2.72% and its price on 08/21/20 lost nearly -2.38%. Currently, there are 23.52M common shares owned by the public and among those 21.85M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for AEZS have a consensus price objective of $4.50. The analysts have set the share’s price value over the next 12 months at a high of $4.50 and a low of $4.50 should the stock experience a downside. But an upside of 88.89% will see the stock hit the forecast high price target while mean target price for the stock is $4.50.

The top 3 mutual fund holders in Aeterna Zentaris Inc. are Fidelity Nasdaq Composite Index F, 1290 VT Micro Cap Portfolio, and Russell Investments US Equity Poo. Fidelity Nasdaq Composite Index F owns 23853.0 shares of the company’s stock, all valued at over $11211.0. Russell Investments US Equity Poo sold 7283.0 shares to bring its total holdings to over 0.0 shares at a value of $0.0. Russell Investments US Equity Poo now owns shares totaling to 0.00% of the shares outstanding.

Shares of Aeterna Zentaris Inc. (NASDAQ: AEZS) opened at $0.5075, down -$0.0 from a prior closing price of $0.51. However, the script later closed the day at $0.50, down -2.38%. The company’s stock has a 5-day price change of -2.72% and -54.09% over the past three months. AEZS shares are trading -45.05% year to date (YTD), with the 12-month market performance down to -75.96% lower. It has a 12-month low price of $0.37 and touched a high of $2.57 over the same period. Currently, 2.73 million shares have been traded, compared to an average intraday trading volume of 4.26 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.39%, -16.15%, and -39.83% respectively.

Institutional ownership of Aeterna Zentaris Inc. (NASDAQ: AEZS) shares accounts for 21.40% of the company’s 23.52M shares outstanding. Mutual fund holders own 0.07%, while other institutional holders and individual stakeholders account for 2.90% and — respectively.

It has a market capitalization of $31.40M and a beta (3y monthly) value of 1.56. The earnings-per-share (ttm) stands at -$0.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.17% over the week and 7.44% over the month.

Analysts forecast that Aeterna Zentaris Inc. (AEZS) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2020. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$0.31 a year ago.

Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the AEZS, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on July 19, 2017, with the firm’s price target at $2-$4. H.C. Wainwright coverage for the Aeterna Zentaris Inc. (AEZS) stock in a research note released on May 10, 2017 offered a Buy rating with a price target of $3. Maxim Group was of a view on May 01, 2017 that the stock is Buy, while Maxim Group gave the stock Buy rating on January 17, 2017, issuing a price target of $7- $10. H.C. Wainwright on their part issued Buy rating on December 02, 2015.


Please enter your comment!
Please enter your name here